• de Francisco ALM, Aljama P, Arias M, Fernandez E, Górriz JL, López-Gómez JM, Martinez-Castelao A, Portoles J: Portolés J,.Anaemia correction in diabetic patients with chronic kidney disease: lessons from the TREAT study.  Nefrologia 2010;30(1):15-20.

• Portolés J, Martinez-Castelao A, Gorriz JL et al: Anemia development and cardiovascular risk management in nonanemic stage 3 CKD. Renal Failure 31:869-875; 2009.

• Lopez-Gomez JM, Portoles JM, Aljama P et al: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int. 2008; S75-S81

• Portoles,J.M.; de Francisco,A.L.; Gorriz,J.L.; Martinez-Castelao,A.; Lopez-Gomez,J.M.; Arias,M.; de la Cruz,J.J.; Cases,A.; Fernandez,E.; Aljama,P: Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study: Kidney Int. 2008; S82-87 .

• Portolés J. López-Gómez J.M. Aljama P. et al: “A prospective multicentre study of the role of anaemia as a riskfactor in haemodialysis patients”. Nephrol Dial Transplant 2007 Feb;22(2):500-7.

• Martin de Francisco AL, Aljama P, Arias M, Gorriz JL, Martinez CA, Portoles J.: “Should we modify hemoglobin targets in CKD patients? FDA and EMEA statements”. NEFROLOGIA .2007; 27 (4):399-404

• Portolés J, López Gómez JM, Gruss E, Aljama P et al:  “Course of vascular acces and relationship with treatment of anemia”. CLIN J AM SOC NEPHROL .2007; 2: 1163-1169

• Portolés J. López-Gómez JM, Aljama P, et al: “Anemia Management And Treatment Response In Patients On Hemodialysis”. Journal of Nephrology: 2006; 19:352-360.

• Portolés J. Lopez Gomez JM, Aljama P, Tato A. et al: "Riesgo cardiovascular en HD en España: prevalencia, pautas de actuación y objetivos" Nefrologia : 2005 N 3 Vol XXVI; 297-306.